Technical Context
I immediately focus not on the word "encryption," but on the effect: the device does not output raw data; only heart rate is exposed. For any serious AI implementation in neurointerfaces, this is almost a dead end because you end up working not with the signal, but with someone else's interpretation of it.
And here's where it gets really frustrating. If the BLE protocol is closed or encrypted to the point that the stream cannot be parsed, I cannot check the sampling rate, artifacts, packet drops, contact quality, channel structure, or even understand what the vendor is actually measuring.
Heart rate alone doesn't save much. It might work for a couple of wellness scenarios, but not for application development where I need access to raw EEG, PPG, or at least intermediate features to build my own processing, filtering, and state detection.
I've specifically compared this context with what I typically see in the consumer neurotracker market. The narrative that "everyone encrypts and hides raw data" is not universal: Muse, for example, usually provides raw EEG access, and the protocol has long been reverse-engineered by the community. So the issue isn't with the device class itself, but with the specific product architecture and the manufacturer's decision to lock the data channel.
For an engineer, this means one simple thing: without raw data, I can't validate a model and can't properly assemble my pipeline. You're left either living with a limited SDK, or hacking together workarounds around ready-made metrics that cannot be independently verified.
What This Changes for Business and Automation
The first hit is to development speed. The team spends weeks not on the product, but on reverse engineering, sniffing, and trying to figure out if any useful stream can be extracted at all.
The second hit is architectural. If the vendor only provides aggregates, then AI automation on top of such a device becomes fragile: you can't retrain models for your own use case, can't reliably adjust thresholds, and can't explain failures to the client.
Only the hardware manufacturer, who maintains control over the ecosystem, wins. Researchers, startups, and anyone hoping to quickly build AI solutions for business based on real biosignals—not marketing APIs—lose out.
At Nahornyi AI Lab, I typically break down such bottlenecks down to the nuts and bolts: where architecture can bypass the limitation, where a different sensor is needed, and where it's more honest to avoid investing in a dead-end integration from the start. If you're facing a similar situation with a device that looks great in a demo but breaks AI automation at the data level, let's take a sober look at the stack and build a viable path without wasting months going nowhere.